miR-133b, down-regulated in a number of tumor types, including esophageal, lung, and colon cancers [100,101,102,103], targets myeloid cell leukemia 1 (MCL1, also known as BCL2L3) and BCL2-like 2 (BCL2L2) [101], oncogenic actinbinding factors like fascin homolog 1 (FSCN1) [102], and the met proto-oncogene receptor tyrosine kinase (MET) [103]. This evidence concerns the gene BCL2L2 and colonic neoplasm.